



Pfizer Limited

The Capital, 1802 / 1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

March 14, 2016

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai - 400 001

The Manager
Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

Dear Sirs,

Sub: Prohibition on sale of drug "Chlopheniramine Maleate + Codeine Syrup"

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Government of India vide Notification No. S.O.909(E) dated March 10, 2016 (which was published on the official Gazette on March 12, 2016), has prohibited the manufacture for sale, sale and distribution of fixed dose combination of Chlopheniramine Maleate + Codeine Syrup with immediate effect.

In view of this, the Company has discontinued the manufacture and sale of its drug "Corex" with immediate effect. Corex has a well-established efficacy and safety profile in India for more than 30 years and Pfizer makes every effort to maintain the highest standards of regulatory and quality compliance in the manufacture and distribution of Corex Cough Syrup. The Company is exploring all available options at its disposal.

The above prohibition is likely to have an adverse impact on the revenue and profitability of the Company. It may be noted that Corex recorded a sale of Rs.176 crores for the nine months period ended December 31, 2015.

We request you to kindly take the above on record.

Thanking you,

Yours truly,
For Pfizer Limited

Prajeet Nair
Company Secretary

CIN: [L24231MH1950PLC008311](#)

✉ contactus.india@pfizer.com

🌐 www.pfizerindia.com